ProteOn XPR36 Protein Interaction Array System

描述（由申请人提供）：犹他州大学的蛋白质相互作用核心设施有兴趣通过收购ProteOn XPR 36阵列光学生物传感器来扩展其当前的生物传感器技术基础。ProteOn是来自Bio-Rad实验室的创新表面等离子体共振平台，为最先进的生物传感器分析设定了新标准。该仪器与该设施现有技术相比具有几个优势，包括增加了配体数量（最多36个）和分析物数量（最多6个）的吞吐量，这些分析物可以使用系统的新型交叉流动池设计同时进行分析。该仪器将在一个完善的大学支持的核心设施内进行维护和操作，其功能是为研究人员提供分子相互作用分析所需的仪器和专业知识。详细描述生物分子的相互作用将有助于揭示与疾病相关的潜在机制，并导致治疗或预防途径。该设施目前雇用一名主任和四名博士-水平的科学家，他们都精通生物传感器技术的应用。这个专门的设施能够支持大量（>70）的内部和外部NIH资助的研究人员。来自犹他州大学校园四个系和三个外部学术机构的九个主要用户的工作被强调，以说明ProteOn技术对涉及阿尔茨海默氏症，细胞凋亡，哮喘，癌症，细胞信号传导和艾滋病毒的广泛项目的影响潜力。这些研究人员中的每一个先前都成功地将生物传感器技术应用于他们的研究中，并且目前都需要这个新平台的增强功能。

DESCRIPTION (provided by applicant): The University of Utah's Protein Interaction Core Facility is interested in expanding its current biosensor technology base by acquiring a ProteOn XPR36 array optical biosensor. The ProteOn is an innovative surface plasmon resonance platform from Bio-Rad Laboratories that sets a new standard for state-of-the-art biosensor analysis. The instrument has several advantages over the Facility's existing technology, including increased throughput in both the number of ligands (up to 36) and number of analytes (up to 6) that can be analyzed simultaneously using the system's novel criss-cross flow cell design. The instrument will be maintained and operated within a well-established University-supported Core Facility whose function is to provide investigators easy access to the instrumentation and expertise required for molecular interaction analysis. Characterizing the interactions of biomolecules in detail will help uncover the underlying mechanisms associated with diseases and lead to cures or avenues of prevention. The Facility currently employs a Director and four Ph.D.-level scientists, all of whom are well versed in the application of biosensor technology. This dedicated Facility is able to support a significant number (>70) of internal and external NIH- funded investigators. The work of nine major users from four departments on the University of Utah campus and three external academic institutions has been highlighted to illustrate the potential of the ProteOn technology to impact a wide range of projects involving Alzheimer's, apoptosis, asthma, cancer, cell signaling, and HIV. Each of these investigators has previously demonstrated success in applying biosensor technology in their research and all have a current need for the enhanced capabilities of this new platform.